DDInter1158 DDInter815
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by _Pseudomonas aeruginosa_.[A233325,A234359,A234364] There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.[A234359,A234364] Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.
Mesalazine {u} (Compound) downregulates {v} (Gene) CNDP2
CNDP2 {u} (Gene) is downregulated by {v} (Compound) Gentamicin
Mesalazine {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Gentamicin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Mesalazine {u} (Compound) downregulates {v} (Gene) CNDP2
CNDP2 {u} (Gene) regulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Gentamicin
Mesalazine {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Tobramycin
Tobramycin {u} (Compound) resembles {v} (Compound) Gentamicin
Mesalazine {u} (Compound) causes {v} (Side Effect) Hypertension
Hypertension {u} (Side Effect) is caused by {v} (Compound) Perindopril
Perindopril {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gentamicin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Gentamicin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neomycin
Neomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Mesalazine {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Mesalazine (Compound) downregulates CNDP2 (Gene) and CNDP2 (Gene) is downregulated by Gentamicin (Compound)
Mesalazine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Gentamicin (Compound)
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Mesalazine (Compound) downregulates CNDP2 (Gene) and CNDP2 (Gene) regulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Gentamicin (Compound)
Mesalazine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Tobramycin (Compound) and Tobramycin (Compound) resembles Gentamicin (Compound)
Mesalazine (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Perindopril (Compound) and Perindopril may cause a minor interaction that can limit clinical effects when taken with Gentamicin
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Gentamicin (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Mesalazine (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin